45,441

Vaccine Group 44,165

22,085 Not Vaccinated

26 Withdrawal by participant
15 Protocol deviation
7 No longer meets eligibility criteria
3 Adverse
4 Other
Received Dose 1
22,030
Discontinuation after dose 1 and before dose 2
108 Withdrawal by participant
89 Lost to follow-up
25 No longer meets eligibility criteria
25 Adverse event
6 Pregnancy
3 Physician decision
2 Death
2 Medication error without adverse event
11 Other / unknown

Received dose 2
21,759
Withdrawal after dose 2
81 Lost to follow up
54 Withdrawal by participant
14 Death
11 Protocol deviation
3 Physician decision
1 Medication error without adverse event
1 Withdrawal by parent / guardian
1 No longer meets eligibility criteria
1 Other

Entered open label follow up

21,592
https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.supplementary-material
 Placebo Group

22,080
26 Withdrawal by participant
12 Protocol deviation
3 No longer meets eligibility criteria
2 Adverse
7 Other
Received Dose 1
22,030
efore dose 2 Discontinuation after dose 1 and before dose 2
108 Withdrawal by participant
90 Lost to follow-up
119 No longer meets eligibility criteria
25 Adverse event
6 Pregnancy
7 Physician decision
2 Death
2 Medication error without adverse event
1 Protocol deviation
20 Other / unknown

Received dose 2
21,650
Withdrawal after dose 2
125 Withdrawal by participant
96 Lost to follow up
24 Protocol deviation
13 Death
6 Other
4 No longer meets eligibility criteria
3 Physician decision
1 Adverse event
1 Pregnancy

Entered open label follow up

21,377
1.supplementary-material
nd before dose 2
 Vaccine Group

COVID-19 occurrence from 7 days after dose 2 in

participants without prior evidence of infection 77 20,712

COVID-19 occurrence from 7 days after dose 2 in

participants with and those without prior evidence
of infection 81 21,642

Infection rate 1 0.372%

Infection rate 1 0.374%

World Population 7,670

Infected population with 100% Vaccination (mn) 29

Infected population with 0% Vaccination (mn) 309

Case Fatality rate (Vaxxed) 0% -

Case Fatality rate (Unvaxxed) 3.0% 9.26

Lives saved 9.26

Placebo group

850 20,713

873 21,689

4.104% 90.9%

4.025% 90.7%

2.1%
 https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.supplementary-material

Adverse event VG PG
21,926 21,921
Any Event 5,524 25.2% 3,048 13.9%
Related 5,241 23.9% 1,311 6.0%
Severe 262 1.2% 150 0.7%
Life-threatening 21 0.1% 26 0.1%
Death 3 0.0% 5 0.0%

VG PG
21,926 21,921
Deaths 15 14
Covid-19 - 2
Covid-19 penumonia 1 -

Fatality rate 0.005% 0.009%

1.75

50%
 7670 mn (World Population)
56 mn (Annual World Deaths)

0.73% Annual death rate

0.37% Half-Yearly death rate

0.009%
 https://www.nejm.org/doi/suppl/10.1056/NEJMoa2110475/suppl_file/nejmoa2110475_appendix.pdf
https://www.contagionlive.com/view/pfizer-covid-19-vaccine-raises-adverse-event-risk-not-as-much-covid-1

Adverse events Vaccinated Adverse Events

Myocarditis 938,812 21 0.0022%

Lymphadenopathy 823,006 660 0.0802%
Appendicitis 900,289 95 0.0106%
Herpes simplex 876,238 219 0.0250%
Herpes zoster infection 888,647 283 0.0318%
Bells Palsy 923,692 81 0.0088%
Myocardial Infarction 892,785 59 0.0066%
Pericarditis 936,197 27 0.0029%

7,670

0.0022%
0.0802%
0.0106%
0.0250%
0.0318%
0.0088%
0.0066%
0.0029%

5.4
33.5
11.0
24.1
22.4
15.1
5.5
a2110475_appendix.pdf
event-risk-not-as-much-covid-19

Covid Infection Adverse Events

183,710 19
159,880 95
176,252 42
170,593 44
175,693 62
180,674 26
176,200 53
183,158 22

309

0.0103% 0.0%
0.0594% 0.0%
0.0238% 0.0%
0.0258% 0.0%
0.0353% 0.0%
0.0144% 0.0%
0.0301% 0.0%
0.0120% 0.0%

0.1
6.0
0.7
1.8
2.3
0.6
0.4

12.1